论文部分内容阅读
目的:探讨ERCC1codon118基因表达对预测三代含铂方案治疗晚期非小细胞肺癌疗效的影响。方法:对我院收治的240例晚期非小细胞肺癌患者进行ERCC1codon118基因多样性检测,以及对各基因型对三代含铂方案治疗晚期非小细胞肺癌疗效进行比较。结果:C/C组与C/T组+T/T组患者其肿瘤分化程度、临床分期、肿瘤大小、血管侵犯等基本资料无明显的相关性(P>0.05);C/C组患者其无进展生存时间以及生存时间、1年、2年以及3年生存率为13.2±5.4月、25.4±4.3月、62.88%、23.48%以及14.39%,明显高于对照组的6.2±4.3月、10.5±3.2月、26.85%、8.33%、1.85%。结论:ERCC1codon118基因表达可能与预测三代含铂方案治疗晚期非小细胞肺癌敏感性有关。
OBJECTIVE: To investigate the effect of ERCC1codon118 gene expression in predicting the efficacy of third-generation platinum-containing regimen in the treatment of advanced non-small cell lung cancer. Methods: The genetic diversity of ERCC1 codon118 gene in 240 patients with advanced non-small cell lung cancer admitted to our hospital and the efficacy of three generations of platinum-containing regimen in the treatment of advanced non-small cell lung cancer were compared. Results: There was no significant correlation between C / C group and C / T group + T / T group (P> 0.05), such as tumor differentiation, clinical stage, tumor size, The progression-free survival time and survival time were 13.2 ± 5.4 months, 25.4 ± 4.3 months, 62.88%, 23.48% and 14.39% respectively, which were significantly higher than those of the control group at 6.2 ± 4.3 months and 10.5 years ± 3.3 months, 26.85%, 8.33%, 1.85%. Conclusion: The expression of ERCC1codon118 gene may be related to the prediction of the sensitivity of third-generation platinum-containing regimen in the treatment of advanced non-small cell lung cancer.